首页 > 最新文献

Romanian Journal of Internal Medicine最新文献

英文 中文
Systematic approach to celiac disease: a comprehensive review for primary providers. 乳糜泻的系统方法:对主要提供者的全面回顾。
IF 1.9 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2022-06-14 Print Date: 2022-06-01 DOI: 10.2478/rjim-2022-0002
Pedro Cortés, Dana M Harris, Yan Bi

Celiac disease is an immune-mediated illness to gluten exposure in genetically susceptible patients. It is characterized by chronic lymphocytic inflammation of the small bowel leading to villous atrophy and its associated complications. The global prevalence of celiac disease is increasing, due in part to improved screening tests and simplified diagnostic criteria. Novel therapies are being developed and include proteolytic enzymes, sequestering agents, and immunotherapies. A strict gluten-free diet, however, remains the mainstay of treatment. In this comprehensive review, we discuss the epidemiology, definitions, diagnosis, and treatment of celiac disease.

乳糜泻是一种免疫介导的疾病,在遗传易感患者接触麸质。它的特点是小肠慢性淋巴细胞炎症导致绒毛萎缩及其相关并发症。乳糜泻的全球患病率正在上升,部分原因是筛查试验的改进和诊断标准的简化。新的治疗方法正在开发,包括蛋白水解酶、隔离剂和免疫疗法。然而,严格的无麸质饮食仍然是治疗的主要方法。在这篇全面的综述中,我们讨论了乳糜泻的流行病学、定义、诊断和治疗。
{"title":"Systematic approach to celiac disease: a comprehensive review for primary providers.","authors":"Pedro Cortés,&nbsp;Dana M Harris,&nbsp;Yan Bi","doi":"10.2478/rjim-2022-0002","DOIUrl":"https://doi.org/10.2478/rjim-2022-0002","url":null,"abstract":"<p><p>Celiac disease is an immune-mediated illness to gluten exposure in genetically susceptible patients. It is characterized by chronic lymphocytic inflammation of the small bowel leading to villous atrophy and its associated complications. The global prevalence of celiac disease is increasing, due in part to improved screening tests and simplified diagnostic criteria. Novel therapies are being developed and include proteolytic enzymes, sequestering agents, and immunotherapies. A strict gluten-free diet, however, remains the mainstay of treatment. In this comprehensive review, we discuss the epidemiology, definitions, diagnosis, and treatment of celiac disease.</p>","PeriodicalId":21463,"journal":{"name":"Romanian Journal of Internal Medicine","volume":"60 2","pages":"93-102"},"PeriodicalIF":1.9,"publicationDate":"2022-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39869112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Peculiar encounter of sarcoidosis and solid pseudopapillary tumor of the pancreas. 胰腺结节病和实性假乳头状瘤的特殊相遇。
IF 1.9 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2022-06-14 Print Date: 2022-06-01 DOI: 10.2478/rjim-2022-0001
Claudia Cobilinschi, Cristian Cobilinschi, Iuliana Trifan, Constantin-Ioan Busuioc, Ruxandra Ionescu, Daniela Opriş-Belinski

Objective: Current literature indicates a connection between sarcoidosis and malignancy, prompting advanced screening in uncertain cases. Solid pseudopapillary tumors (SPT) of the pancreas are rare entities that can be confirmed by adding imaging results to immunohistochemistry staining. The aim of this article is to describe a rare association of sarcoidosis and SPT.Materials and methods: Case report.Results: A young female patient with no prior medical history presents with shortness of breath and fatigue. The diagnosis of pulmonary and hepatic sarcoidosis is placed upon laboratory and radiographic changes. Intermittent abdominal pain prompts an MRI that shows the presence of a tumoral mass in the tail of the pancreas. Surgical resection of the mass is performed and histological examination indicates a SPT, subsequently confirmed by immunohistochemistry.Conclusion: This is the third reported case of concomitant sarcoidosis and solid pseudopapillary tumor of the pancreas.

目的:目前的文献表明结节病与恶性肿瘤之间存在联系,提示在不确定的病例中进行早期筛查。胰腺的实性假乳头状肿瘤(SPT)是罕见的实体,可以通过免疫组织化学染色的影像结果来证实。本文的目的是描述结节病和SPT的罕见关联。材料与方法:病例报告。结果:一名年轻女性患者,无既往病史,表现为呼吸短促和疲劳。肺和肝结节病的诊断取决于实验室和影像学的改变。间歇性腹痛提示MRI显示胰腺尾部有肿瘤肿块。手术切除肿块,组织学检查显示SPT,随后免疫组织化学证实。结论:这是报告的第三例胰腺结节病合并实性假乳头状瘤。
{"title":"Peculiar encounter of sarcoidosis and solid pseudopapillary tumor of the pancreas.","authors":"Claudia Cobilinschi,&nbsp;Cristian Cobilinschi,&nbsp;Iuliana Trifan,&nbsp;Constantin-Ioan Busuioc,&nbsp;Ruxandra Ionescu,&nbsp;Daniela Opriş-Belinski","doi":"10.2478/rjim-2022-0001","DOIUrl":"https://doi.org/10.2478/rjim-2022-0001","url":null,"abstract":"<p><p><b>Objective:</b> Current literature indicates a connection between sarcoidosis and malignancy, prompting advanced screening in uncertain cases. Solid pseudopapillary tumors (SPT) of the pancreas are rare entities that can be confirmed by adding imaging results to immunohistochemistry staining. The aim of this article is to describe a rare association of sarcoidosis and SPT.<b>Materials and methods:</b> Case report.<b>Results</b>: A young female patient with no prior medical history presents with shortness of breath and fatigue. The diagnosis of pulmonary and hepatic sarcoidosis is placed upon laboratory and radiographic changes. Intermittent abdominal pain prompts an MRI that shows the presence of a tumoral mass in the tail of the pancreas. Surgical resection of the mass is performed and histological examination indicates a SPT, subsequently confirmed by immunohistochemistry.<b>Conclusion:</b> This is the third reported case of concomitant sarcoidosis and solid pseudopapillary tumor of the pancreas.</p>","PeriodicalId":21463,"journal":{"name":"Romanian Journal of Internal Medicine","volume":"60 2","pages":"132-137"},"PeriodicalIF":1.9,"publicationDate":"2022-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39855096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anti-cyclic citrullinated peptide antibody-positive rheumatoid arthritis caused by bacterial organizing pneumonia in a patient with Sjogren's syndrome. 抗环瓜氨酸肽抗体阳性的类风湿关节炎由细菌性肺炎引起的干燥综合征患者。
IF 1.9 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2022-06-14 Print Date: 2022-06-01 DOI: 10.2478/rjim-2022-0003
Taro Horino, Mitsuharu Yoshida, Satoshi Inotani, Kazuki Anabuki, Hiroshi Ohnishi, Masahiro Komori, Osamu Ichii, Yoshio Terada

A 58-year-old woman with a history of Sjogren's syndrome was admitted to our hospital with cough, decreased right lung breath sounds and arthralgia in both thumbs. Chest computed tomography showed consolidation with air bronchogram in the right lung. Levels of anti-cyclic citrullinated peptide antibody and rheumatoid factor levels were significantly elevated. She was diagnosed with rheumatoid arthritis induced by bacterial organizing pneumonia. Treatment with salazosulfapyridine was added for rheumatoid arthritis and arthralgia gradually improved. This case highlights that respiratory infections could lead to anti-cyclic citrullinated peptide antibody-positive rheumatoid arthritis in patients with Sjogren's syndrome.

一名58岁女性,有干燥综合征病史,因咳嗽、右肺呼吸音减少和双拇指关节痛入院。胸部电脑断层显示右肺实变伴支气管充气征。抗环瓜氨酸肽抗体水平和类风湿因子水平显著升高。她被诊断为细菌性组织肺炎引起的类风湿关节炎。类风湿关节炎加用萨拉唑磺胺吡啶治疗,关节痛逐渐好转。本病例强调呼吸道感染可导致干燥综合征患者出现抗环瓜氨酸肽抗体阳性的类风湿关节炎。
{"title":"Anti-cyclic citrullinated peptide antibody-positive rheumatoid arthritis caused by bacterial organizing pneumonia in a patient with Sjogren's syndrome.","authors":"Taro Horino,&nbsp;Mitsuharu Yoshida,&nbsp;Satoshi Inotani,&nbsp;Kazuki Anabuki,&nbsp;Hiroshi Ohnishi,&nbsp;Masahiro Komori,&nbsp;Osamu Ichii,&nbsp;Yoshio Terada","doi":"10.2478/rjim-2022-0003","DOIUrl":"https://doi.org/10.2478/rjim-2022-0003","url":null,"abstract":"<p><p>A 58-year-old woman with a history of Sjogren's syndrome was admitted to our hospital with cough, decreased right lung breath sounds and arthralgia in both thumbs. Chest computed tomography showed consolidation with air bronchogram in the right lung. Levels of anti-cyclic citrullinated peptide antibody and rheumatoid factor levels were significantly elevated. She was diagnosed with rheumatoid arthritis induced by bacterial organizing pneumonia. Treatment with salazosulfapyridine was added for rheumatoid arthritis and arthralgia gradually improved. This case highlights that respiratory infections could lead to anti-cyclic citrullinated peptide antibody-positive rheumatoid arthritis in patients with Sjogren's syndrome.</p>","PeriodicalId":21463,"journal":{"name":"Romanian Journal of Internal Medicine","volume":"60 2","pages":"127-131"},"PeriodicalIF":1.9,"publicationDate":"2022-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39869114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Serum uric acid as a predictor of cardio- and cerebro-vascular diseases in maintenance hemodialysis patients. 血清尿酸作为维持性血液透析患者心脑血管疾病的预测因子。
IF 1.9 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2022-06-14 Print Date: 2022-06-01 DOI: 10.2478/rjim-2021-0039
Najmeh Khodabandeh, Elahe Taziki, Toktam Alirezaei

Background: Hyperuricemia is associated with an increased risk of cardio-and cerebrovascular disease (CVD) in general population. However, in the hemodialysis (HD) patients, low serum uric acid (SUA) increases the risk of mortality. Considering that CVD is the principal cause of death among maintenance HD patients, the present study aimed to determine the predictive value of SUA for CVD outcome in this population.Methods: In this two-year follow-up prospective study, 205 outpatients under maintenance HD were enrolled from March 2017 to 2020. Patients' demographic data, underlying diseases, and the results of serum tests, as well as two-year follow-up results of CVD events and mortality were recorded.Results: A total of 130 (63%) patients were eligible for analysis; 62.9% were male; mean age of participants was 59±13years. At follow-up, coronary artery disease was observed in 43.2%, peripheral artery disease in 26.5%, and cerebrovascular disease in 20.5%; angiography was required in 52.3% and 4.5% died of CVD. SUA was ≤5.4 mg/dL in 52 patients, 5.5-6.1 mg/dL in 19, and ≥6.2 mg/dL in 59 patients with significant difference based on mean age, sex distribution, occurrence of cerebrovascular disease and cardiovascular mortality (P<0.05). Patients with cerebrovascular disease had a significantly lower SUA levels (P=0.006). Logistic regression showed the significant effect of SUA on the occurrence of cerebrovascular disease (P=0.008).Conclusion: Low SUA can predict two-year incidence of cerebrovascular disease in HD patients. However, SUA levels did not show significant predictive effect on two-year coronary events, peripheral artery disease and cardiovascular mortality.

背景:在普通人群中,高尿酸血症与心脑血管疾病(CVD)的风险增加有关。然而,在血液透析(HD)患者中,低血清尿酸(SUA)增加了死亡的风险。考虑到心血管疾病是维持性HD患者的主要死亡原因,本研究旨在确定SUA对该人群心血管疾病结局的预测价值。方法:在这项为期两年的随访前瞻性研究中,从2017年3月至2020年,纳入205例维持性HD门诊患者。记录患者的人口统计数据、基础疾病、血清测试结果以及心血管疾病事件和死亡率的两年随访结果。结果:共有130例(63%)患者符合分析条件;男性占62.9%;参与者平均年龄59±13岁。随访时,冠状动脉疾病43.2%,外周动脉疾病26.5%,脑血管疾病20.5%;52.3%的患者需要血管造影,4.5%的患者死于心血管疾病。52例患者SUA≤5.4 mg/dL, 19例患者5.5-6.1 mg/dL, 59例患者SUA≥6.2 mg/dL,在平均年龄、性别分布、脑血管疾病发生及心血管病死率等方面存在显著差异(结论:低SUA可预测HD患者2年脑血管疾病的发病率)。然而,SUA水平对两年冠状动脉事件、外周动脉疾病和心血管死亡率没有显著的预测作用。
{"title":"Serum uric acid as a predictor of cardio- and cerebro-vascular diseases in maintenance hemodialysis patients.","authors":"Najmeh Khodabandeh,&nbsp;Elahe Taziki,&nbsp;Toktam Alirezaei","doi":"10.2478/rjim-2021-0039","DOIUrl":"https://doi.org/10.2478/rjim-2021-0039","url":null,"abstract":"<p><p><b>Background:</b> Hyperuricemia is associated with an increased risk of cardio-and cerebrovascular disease (CVD) in general population. However, in the hemodialysis (HD) patients, low serum uric acid (SUA) increases the risk of mortality. Considering that CVD is the principal cause of death among maintenance HD patients, the present study aimed to determine the predictive value of SUA for CVD outcome in this population.<b>Methods:</b> In this two-year follow-up prospective study, 205 outpatients under maintenance HD were enrolled from March 2017 to 2020. Patients' demographic data, underlying diseases, and the results of serum tests, as well as two-year follow-up results of CVD events and mortality were recorded.<b>Results:</b> A total of 130 (63%) patients were eligible for analysis; 62.9% were male; mean age of participants was 59±13years. At follow-up, coronary artery disease was observed in 43.2%, peripheral artery disease in 26.5%, and cerebrovascular disease in 20.5%; angiography was required in 52.3% and 4.5% died of CVD. SUA was ≤5.4 mg/dL in 52 patients, 5.5-6.1 mg/dL in 19, and ≥6.2 mg/dL in 59 patients with significant difference based on mean age, sex distribution, occurrence of cerebrovascular disease and cardiovascular mortality (P<0.05). Patients with cerebrovascular disease had a significantly lower SUA levels (P=0.006). Logistic regression showed the significant effect of SUA on the occurrence of cerebrovascular disease (P=0.008).<b>Conclusion:</b> Low SUA can predict two-year incidence of cerebrovascular disease in HD patients. However, SUA levels did not show significant predictive effect on two-year coronary events, peripheral artery disease and cardiovascular mortality.</p>","PeriodicalId":21463,"journal":{"name":"Romanian Journal of Internal Medicine","volume":"60 2","pages":"115-122"},"PeriodicalIF":1.9,"publicationDate":"2022-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39672670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19: a trigger for severe thrombotic microangiopathy in a patient with complement gene variant. COVID-19:补体基因变异患者严重血栓性微血管病变的触发因素
IF 1.9 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2022-06-14 Print Date: 2022-06-01 DOI: 10.2478/rjim-2021-0040
Larisa Pinte, Bogdan Marian Sorohan, Zoltán Prohászka, Mihaela Gherghiceanu, Cristian Băicuş

The evidence regarding thrombotic microangiopathy (TMA) related to Coronavirus Infectious Disease 2019 (COVID-19) in patients with complement gene mutations as a cause of acute kidney injury (AKI) are limited. We presented the case of a 23-year-old male patient admitted with an asymptomatic form of COVID-19, but with uncontrolled hypertension and AKI. Kidney biopsy showed severe lesions of TMA. In evolution patient had persistent microangiopathic hemolytic anemia, decreased level of haptoglobin and increased LDH level. Decreased complement C3 level and the presence of schistocytes were found for the first time after biopsy. Kidney function progressively decreased and the patient remained hemodialysis dependent. Complement work-up showed a heterozygous variant with unknown significance in complement factor I (CFI) c.-13G>A, affecting the 5' UTR region of the gene. In addition, the patient was found to be heterozygous for the complement factor H (CFH) H3 haplotype (involving the rare alleles of c.-331C>T, Q672Q and E936D polymorphisms) reported as a risk factor of atypical hemolytic uremic syndrome. This case of AKI associated with severe TMA and secondary hemolytic uremic syndrome highlights the importance of genetic risk modifiers in the alternative pathway dysregulation of the complement in the setting of COVID-19, even in asymptomatic forms.

补体基因突变患者中与2019冠状病毒传染病(COVID-19)相关的血栓性微血管病变(TMA)作为急性肾损伤(AKI)原因的证据有限。我们报告了一例23岁的男性患者,入院时患有无症状的COVID-19,但高血压和AKI未得到控制。肾活检显示严重的TMA病变。演进过程中患者有持续性微血管病变性溶血性贫血,触珠蛋白水平降低,LDH水平升高。活检后首次发现补体C3水平降低,存在血吸虫细胞。肾功能逐渐下降,患者仍然依赖血液透析。补体检查显示补体因子I (CFI) c - 13g > a的杂合变异,影响基因的5' UTR区域,意义未知。此外,该患者被发现为补体因子H (CFH) H3单倍型杂合(涉及c - 331c >T, Q672Q和E936D多态性的罕见等位基因),这是报道的非典型溶血性尿毒症综合征的危险因素。本例AKI合并严重TMA和继发性溶血性尿毒症综合征,突出了遗传风险修饰因子在COVID-19背景下补体替代途径失调中的重要性,即使在无症状形式中也是如此。
{"title":"COVID-19: a trigger for severe thrombotic microangiopathy in a patient with complement gene variant.","authors":"Larisa Pinte,&nbsp;Bogdan Marian Sorohan,&nbsp;Zoltán Prohászka,&nbsp;Mihaela Gherghiceanu,&nbsp;Cristian Băicuş","doi":"10.2478/rjim-2021-0040","DOIUrl":"https://doi.org/10.2478/rjim-2021-0040","url":null,"abstract":"<p><p>The evidence regarding thrombotic microangiopathy (TMA) related to Coronavirus Infectious Disease 2019 (COVID-19) in patients with complement gene mutations as a cause of acute kidney injury (AKI) are limited. We presented the case of a 23-year-old male patient admitted with an asymptomatic form of COVID-19, but with uncontrolled hypertension and AKI. Kidney biopsy showed severe lesions of TMA. In evolution patient had persistent microangiopathic hemolytic anemia, decreased level of haptoglobin and increased LDH level. Decreased complement C3 level and the presence of schistocytes were found for the first time after biopsy. Kidney function progressively decreased and the patient remained hemodialysis dependent. Complement work-up showed a heterozygous variant with unknown significance in complement factor I (CFI) c.-13G>A, affecting the 5' UTR region of the gene. In addition, the patient was found to be heterozygous for the complement factor H (CFH) H3 haplotype (involving the rare alleles of c.-331C>T, Q672Q and E936D polymorphisms) reported as a risk factor of atypical hemolytic uremic syndrome. This case of AKI associated with severe TMA and secondary hemolytic uremic syndrome highlights the importance of genetic risk modifiers in the alternative pathway dysregulation of the complement in the setting of COVID-19, even in asymptomatic forms.</p>","PeriodicalId":21463,"journal":{"name":"Romanian Journal of Internal Medicine","volume":"60 2","pages":"138-142"},"PeriodicalIF":1.9,"publicationDate":"2022-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39672671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Acute myelogenous leukemia - current recommendations and approaches in molecular-genetic assessment. 急性髓性白血病-分子遗传学评估的当前建议和方法。
IF 1.9 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2022-06-14 Print Date: 2022-06-01 DOI: 10.2478/rjim-2022-0004
Dinnar Yahya, Mari Hachmeriyan, Ilina Micheva, Trifon Chervenkov

Acute myelogenous leukemia is a multi-step hematological malignancy, affecting function, growth, proliferation and cell cycle of myeloid precursors. Overall assessment of patients with the disease requires among everything else, a comprehensive investigation of the genetic basis through various methods such as cytogenetic and molecular-genetic ones. This clarification provides diagnostic refinement and carries prognostic and predictive value in respect of essential therapeutic choices.With this review of the literature, we focus on summarizing the latest recommendations and preferred genetic methods, as well as on emphasizing on their general benefits and limitations. Since none of these methods is actually totipotent, we also aim to shed light over the often-difficult choice of appropriate genetic analyses.

急性髓性白血病是一种多步骤的血液系统恶性肿瘤,影响骨髓前体细胞的功能、生长、增殖和细胞周期。对患者进行全面评估,首先需要通过细胞遗传学和分子遗传学等多种方法对遗传基础进行全面调查。这种澄清提供了诊断的精细化,并在基本治疗选择方面具有预后和预测价值。通过对文献的回顾,我们重点总结了最新的推荐和首选的遗传方法,并强调了它们的一般优点和局限性。由于这些方法中没有一种是全能的,我们还旨在阐明通常很难选择适当的基因分析。
{"title":"Acute myelogenous leukemia - current recommendations and approaches in molecular-genetic assessment.","authors":"Dinnar Yahya,&nbsp;Mari Hachmeriyan,&nbsp;Ilina Micheva,&nbsp;Trifon Chervenkov","doi":"10.2478/rjim-2022-0004","DOIUrl":"https://doi.org/10.2478/rjim-2022-0004","url":null,"abstract":"<p><p>Acute myelogenous leukemia is a multi-step hematological malignancy, affecting function, growth, proliferation and cell cycle of myeloid precursors. Overall assessment of patients with the disease requires among everything else, a comprehensive investigation of the genetic basis through various methods such as cytogenetic and molecular-genetic ones. This clarification provides diagnostic refinement and carries prognostic and predictive value in respect of essential therapeutic choices.With this review of the literature, we focus on summarizing the latest recommendations and preferred genetic methods, as well as on emphasizing on their general benefits and limitations. Since none of these methods is actually totipotent, we also aim to shed light over the often-difficult choice of appropriate genetic analyses.</p>","PeriodicalId":21463,"journal":{"name":"Romanian Journal of Internal Medicine","volume":"60 2","pages":"103-114"},"PeriodicalIF":1.9,"publicationDate":"2022-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39633418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Stroke risk scores for prediction of mortality and hemorrhages in atrial fibrillation patients 预测房颤患者死亡率和出血的卒中风险评分
IF 1.9 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2022-06-10 DOI: 10.2478/rjim-2022-0009
A. Ivănescu, C. Delcea, G. Dan
Abstract Background: Atrial fibrillation (AF) is an emerging epidemic worldwide, responsible for a twofold increase in mortality, independent of other risk factors. Stroke prevention is the cornerstone of AF management. However, oral anticoagulation imposes an increased risk of bleeding. Several risk scores have been developed for estimating both the thromboembolic and the bleeding risks. The aim of the study was to determine the usefulness of different stroke risk scores as predictors of mortality and hemorrhagic events in AF patients. Methods: We retrospectively enrolled 211 AF patients hospitalized in the Cardiology Ward of our tertiary hospital. The primary endpoints were mortality and non-minor bleeding events. The mean follow-up period was 378 days for bleeding events and 5 years and 1 month for mortality. For each patient, we evaluated the following stroke risk scores: CHADS2, CHA2DS2-VASc, R2CHADS2, ABC, ATRIA, GARFIELD. Results: The mean age in our cohort is 66, with a slight predominance of women (52.2%). For a CHA2DS2-VASc ≥ 4 as well as for a score of 2-3, 5-year survival was worse than for patients with a score of 0–1(chi-squared=8.13; p=0.01). Similarly, all subgroups of patients with an ABC <2%, had a worse 5-year survival when compared with an ABC score of ≥2% (chi-squared=12.85; p=0.005). C-statistics show a modest predictive value for mortality, for all stroke scores except Garfield, with similar AUCs, the highest being for CHA2DS2-VASc (AUC 0.656; p=0.0001). CHA2DS2-VASc also correlates with bleeding events, having a good predictive ability (AUC 0.723; 95%CI 0.658–0.782, p=0.001), mildly superior to HAS-BLED (AUC 0.674; 95% CI 0.523–0.825; p = 0.04) and very close to Garfield-bleeding (0.765; 95%CI 0.702–0.80; p=0.0001). Conclusions: CHA2DS2-VASc is comparable to HAS-BLED and Garfield-bleeding in predicting bleeding events in AF patients. CHA2DS2-VASc and ABC correlate directly and consistently with mortality rate. For CHA2DS2-VASc, the AUCs for our endpoints are similar to the ones for stroke prediction, highlighting the potential of extending its applicability to various outcomes.
背景:房颤(AF)是一种新兴的全球流行病,其死亡率增加了两倍,独立于其他危险因素。卒中预防是房颤管理的基石。然而,口服抗凝剂会增加出血的风险。已经开发了几种风险评分来评估血栓栓塞和出血风险。该研究的目的是确定不同卒中风险评分作为房颤患者死亡率和出血性事件预测因子的有效性。方法:回顾性分析我院三级医院心内科住院的房颤患者211例。主要终点是死亡率和非轻微出血事件。出血事件的平均随访时间为378天,死亡的平均随访时间为5年零1个月。对于每位患者,我们评估了以下卒中风险评分:CHADS2, CHA2DS2-VASc, R2CHADS2, ABC,心房,GARFIELD。结果:本组患者的平均年龄为66岁,女性略占优势(52.2%)。对于CHA2DS2-VASc≥4以及评分为2-3的患者,5年生存率低于评分为0-1的患者(卡方=8.13;p = 0.01)。同样,与ABC评分≥2%的患者相比,ABC评分<2%的所有亚组患者的5年生存率都较差(卡方=12.85;p = 0.005)。c -统计数据显示,除Garfield外,所有卒中评分对死亡率的预测价值不大,AUC相似,最高的是CHA2DS2-VASc (AUC 0.656;p = 0.0001)。CHA2DS2-VASc也与出血事件相关,具有良好的预测能力(AUC 0.723;95%CI 0.658-0.782, p=0.001),略优于HAS-BLED (AUC 0.674;95% ci 0.523-0.825;p = 0.04),非常接近加菲猫出血(0.765;95%可信区间0.702 - -0.80;p = 0.0001)。结论:CHA2DS2-VASc在预测AF患者出血事件方面与HAS-BLED和Garfield-bleeding相当。CHA2DS2-VASc和ABC与死亡率直接一致相关。对于CHA2DS2-VASc,我们的终点的auc与卒中预测的auc相似,这突出了将其扩展到各种结果的适用性的潜力。
{"title":"Stroke risk scores for prediction of mortality and hemorrhages in atrial fibrillation patients","authors":"A. Ivănescu, C. Delcea, G. Dan","doi":"10.2478/rjim-2022-0009","DOIUrl":"https://doi.org/10.2478/rjim-2022-0009","url":null,"abstract":"Abstract Background: Atrial fibrillation (AF) is an emerging epidemic worldwide, responsible for a twofold increase in mortality, independent of other risk factors. Stroke prevention is the cornerstone of AF management. However, oral anticoagulation imposes an increased risk of bleeding. Several risk scores have been developed for estimating both the thromboembolic and the bleeding risks. The aim of the study was to determine the usefulness of different stroke risk scores as predictors of mortality and hemorrhagic events in AF patients. Methods: We retrospectively enrolled 211 AF patients hospitalized in the Cardiology Ward of our tertiary hospital. The primary endpoints were mortality and non-minor bleeding events. The mean follow-up period was 378 days for bleeding events and 5 years and 1 month for mortality. For each patient, we evaluated the following stroke risk scores: CHADS2, CHA2DS2-VASc, R2CHADS2, ABC, ATRIA, GARFIELD. Results: The mean age in our cohort is 66, with a slight predominance of women (52.2%). For a CHA2DS2-VASc ≥ 4 as well as for a score of 2-3, 5-year survival was worse than for patients with a score of 0–1(chi-squared=8.13; p=0.01). Similarly, all subgroups of patients with an ABC <2%, had a worse 5-year survival when compared with an ABC score of ≥2% (chi-squared=12.85; p=0.005). C-statistics show a modest predictive value for mortality, for all stroke scores except Garfield, with similar AUCs, the highest being for CHA2DS2-VASc (AUC 0.656; p=0.0001). CHA2DS2-VASc also correlates with bleeding events, having a good predictive ability (AUC 0.723; 95%CI 0.658–0.782, p=0.001), mildly superior to HAS-BLED (AUC 0.674; 95% CI 0.523–0.825; p = 0.04) and very close to Garfield-bleeding (0.765; 95%CI 0.702–0.80; p=0.0001). Conclusions: CHA2DS2-VASc is comparable to HAS-BLED and Garfield-bleeding in predicting bleeding events in AF patients. CHA2DS2-VASc and ABC correlate directly and consistently with mortality rate. For CHA2DS2-VASc, the AUCs for our endpoints are similar to the ones for stroke prediction, highlighting the potential of extending its applicability to various outcomes.","PeriodicalId":21463,"journal":{"name":"Romanian Journal of Internal Medicine","volume":"7 1","pages":"182 - 192"},"PeriodicalIF":1.9,"publicationDate":"2022-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82059142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Lung cancer and combined pulmonary fibrosis and emphysema with anti-ARS antibody 肺癌及合并肺纤维化、肺气肿伴抗ars抗体
IF 1.9 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2022-05-22 DOI: 10.2478/rjim-2022-0008
Riho Tanimura, Kengo Nishino, Ryosuke Iwade, Ryo Abe, S. Okauchi, Y. Sasatani, H. Satoh
Abstract A 59-year-old man who had smoked for 23 pack-years was admitted to our hospital because of two-month history of back pain. The chest computed tomography scan demonstrated combined pulmonary fibrosis and emphysema (CPFE) and an irregular shaped nodule in the left lower lobe of the lung. A biopsy obtained from samples from subcarinal lymph nodes revealed non-small cell lung cancer. Anti-aminoacyl-tRNA synthetase (ARS) antibody was elevated up to 166 U/mL, although he had no symptoms suggestive connective tissue diseases. It is well known that most of CPFE patients are current or former heavy smokers, and some researchers described the relationship between CPFE and connective tissue diseases. To our best knowledge, this was the first report of lung cancer in patient with anti-ARS antibody-positive CPFE. In some anti-ARS antibody-positive patients, smoking might have a relationship with development of CPFE and lung cancer.
摘要一位吸烟23包年的59岁男性因2个月的背痛病史入院。胸部计算机断层扫描显示合并肺纤维化和肺气肿(CPFE)和左肺下叶不规则形状的结节。从隆突下淋巴结样本中获得的活检显示非小细胞肺癌。抗氨基酰基trna合成酶(ARS)抗体升高至166 U/mL,尽管他没有结缔组织疾病的症状。众所周知,大多数CPFE患者是当前或曾经的重度吸烟者,一些研究人员描述了CPFE与结缔组织疾病之间的关系。据我们所知,这是首例抗ars抗体阳性CPFE患者发生肺癌的报道。在一些抗ars抗体阳性的患者中,吸烟可能与CPFE和肺癌的发生有关。
{"title":"Lung cancer and combined pulmonary fibrosis and emphysema with anti-ARS antibody","authors":"Riho Tanimura, Kengo Nishino, Ryosuke Iwade, Ryo Abe, S. Okauchi, Y. Sasatani, H. Satoh","doi":"10.2478/rjim-2022-0008","DOIUrl":"https://doi.org/10.2478/rjim-2022-0008","url":null,"abstract":"Abstract A 59-year-old man who had smoked for 23 pack-years was admitted to our hospital because of two-month history of back pain. The chest computed tomography scan demonstrated combined pulmonary fibrosis and emphysema (CPFE) and an irregular shaped nodule in the left lower lobe of the lung. A biopsy obtained from samples from subcarinal lymph nodes revealed non-small cell lung cancer. Anti-aminoacyl-tRNA synthetase (ARS) antibody was elevated up to 166 U/mL, although he had no symptoms suggestive connective tissue diseases. It is well known that most of CPFE patients are current or former heavy smokers, and some researchers described the relationship between CPFE and connective tissue diseases. To our best knowledge, this was the first report of lung cancer in patient with anti-ARS antibody-positive CPFE. In some anti-ARS antibody-positive patients, smoking might have a relationship with development of CPFE and lung cancer.","PeriodicalId":21463,"journal":{"name":"Romanian Journal of Internal Medicine","volume":"24 1","pages":"193 - 196"},"PeriodicalIF":1.9,"publicationDate":"2022-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81971156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A pilot study of changes in urinary podocalyxin levels during normal pregnancy and labor 正常妊娠和分娩期间尿足alyxin水平变化的初步研究
IF 1.9 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2022-05-06 DOI: 10.2478/rjim-2022-0007
Ylbe Palacios de Franco, N. Segovia, Ylbe Franco Marx, Rudiona Hoxhaj, Carlos Franco Palacios
Abstract Introduction: Increased urinary podocalyxin, a surrogate marker of podocyte detachment, has been shown in preeclampsia and eclampsia, but there is a paucity of data of the effect of normal pregnancy on its urinary excretion. We aimed to describe these changes in this pilot study. Methods: Urine podocalyxin levels were measured in 115 pregnant women. Of these, 12 women were in the second trimester of gestation, 57 in the third trimester and 46 women were in labor. Results: The median [IQR] urinary podocalyxin levels were 0.81 [0.27, 3.68], 0.92 [0.44, 5.49] and 64.7 [30.5, 106.3] ng/mg creatinine in the second trimester, third trimester, and during labor, respectively (p<0.0001). Patients with hematuria during labor had higher levels of urinary podocalyxin (128.6 [79.8, 169.6] ng/mg creatinine. There was a moderate correlation between gestational age and urinary podocalyxin levels (r=0.63, p<0.0001). Conclusion: Urinary podocalyxin levels were low in normal pregnancies and increased significantly during labor and with hematuria.
摘要:尿足alyxin(足细胞脱离的替代标志物)的增加已在子痫前期和子痫中被发现,但缺乏正常妊娠对其尿排泄的影响的数据。我们的目的是在这个初步研究中描述这些变化。方法:测定115例孕妇尿足霉素水平。其中,12名妇女处于妊娠中期,57名处于妊娠晚期,46名妇女处于分娩阶段。结果:妊娠中期、妊娠晚期和分娩时尿足alyxin的中位数[IQR]分别为0.81[0.27,3.68]、0.92[0.44,5.49]和64.7 [30.5,106.3]ng/mg肌酐(p<0.0001)。分娩时有血尿的患者尿足alyxin水平较高(128.6 [79.8,169.6]ng/mg肌酐)。胎龄与尿足alyxin水平有中度相关性(r=0.63, p<0.0001)。结论:尿足alyxin水平在正常妊娠时较低,在分娩和血尿时明显升高。
{"title":"A pilot study of changes in urinary podocalyxin levels during normal pregnancy and labor","authors":"Ylbe Palacios de Franco, N. Segovia, Ylbe Franco Marx, Rudiona Hoxhaj, Carlos Franco Palacios","doi":"10.2478/rjim-2022-0007","DOIUrl":"https://doi.org/10.2478/rjim-2022-0007","url":null,"abstract":"Abstract Introduction: Increased urinary podocalyxin, a surrogate marker of podocyte detachment, has been shown in preeclampsia and eclampsia, but there is a paucity of data of the effect of normal pregnancy on its urinary excretion. We aimed to describe these changes in this pilot study. Methods: Urine podocalyxin levels were measured in 115 pregnant women. Of these, 12 women were in the second trimester of gestation, 57 in the third trimester and 46 women were in labor. Results: The median [IQR] urinary podocalyxin levels were 0.81 [0.27, 3.68], 0.92 [0.44, 5.49] and 64.7 [30.5, 106.3] ng/mg creatinine in the second trimester, third trimester, and during labor, respectively (p<0.0001). Patients with hematuria during labor had higher levels of urinary podocalyxin (128.6 [79.8, 169.6] ng/mg creatinine. There was a moderate correlation between gestational age and urinary podocalyxin levels (r=0.63, p<0.0001). Conclusion: Urinary podocalyxin levels were low in normal pregnancies and increased significantly during labor and with hematuria.","PeriodicalId":21463,"journal":{"name":"Romanian Journal of Internal Medicine","volume":"68 1","pages":"160 - 165"},"PeriodicalIF":1.9,"publicationDate":"2022-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85313770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidermal Growth Factor Receptor immunohistochemical expression in hepatocellular carcinoma without Epidermal Growth Factor Receptor exons 18–21 mutations 无表皮生长因子受体外显子18-21突变的肝细胞癌中表皮生长因子受体的免疫组化表达
IF 1.9 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2022-04-27 DOI: 10.2478/rjim-2022-0006
D. Nikolova, M. Trajkovska, Emilija Nikolovska Trpcevska, A. Eftimov, Rubens Jovanovik, V. Janevska
Abstract Introduction: EGFR targeted therapies, have been proved beneficial for patients with HCC, nevertheless additional research on EGFR immunoexpresion and EGFR mutations is still needed, especially in population in which it has not been done yet. The aim of this study is to evaluate EGFR immunoexpression in HCC without EGFR exons 18–21 mutations and to evaluate its influence on survival in HCC patients in North Macedonia. Methods: We studied 31 cases of HCC for EGFR immunohistochemical expression and EGFR exons 18–21 mutations. The following clinical parameters were analyzed: Hepatitis B and C virus infection, presence of cirrhosis, tumor size, enlarged lymph nodes, metastases, alpha fetoprotein level and overall survival. Presence of the EGFR immunosignal (membranous and cytoplasmic) and the percentage of positive tumor cells in the entire tumor tissue specimen were semi-quantitatively determined. Results: Hepatitis B and C virus infection, tumor size, metastatic disease and EGFR immunoexpression have influence on patient’s survival. No EGFR exons 18–21 mutations were detected in this group of HCCs. EGFR expression of 61%–80% in tumor tissue significantly influenced survival of the patients (p < 0.01). Multiple Cox regression confirmed tumor size of 5–10 cm (p < 0.05), tumor size > 10 cm (p < 0.01) and EGFR expression in range of 61% to 80% (p < 0.05) as independent survival predictors in patients with HCC. Conclusion: EGFR overexpression in range of 61% to 80% was an independent survival predictor in patients with HCC, implying that these patients could benefit from EGFR inhibition. However, the absence of EGFR mutations in exons 18–21 in any of the cases of this study suggest that single drug EGFR targeted therapy in patients with HCC may be insufficient.
摘要:EGFR靶向治疗已被证明对HCC患者有益,但仍需要进一步研究EGFR免疫表达和EGFR突变,特别是在尚未进行研究的人群中。本研究的目的是评估EGFR免疫表达在没有EGFR外显子18-21突变的HCC中,并评估其对北马其顿HCC患者生存的影响。方法:对31例肝癌患者进行EGFR免疫组化表达及EGFR外显子18-21突变的研究。分析以下临床参数:乙型和丙型肝炎病毒感染、肝硬化的存在、肿瘤大小、淋巴结肿大、转移、甲胎蛋白水平和总生存率。半定量测定EGFR免疫信号(膜质和细胞质)的存在以及整个肿瘤组织标本中阳性肿瘤细胞的百分比。结果:乙型和丙型肝炎病毒感染、肿瘤大小、转移性及EGFR免疫表达均影响患者的生存。在这组hcc中未检测到EGFR外显子18-21突变。EGFR在肿瘤组织中表达61% ~ 80%显著影响患者的生存(p < 0.01)。多重Cox回归证实肿瘤大小5 ~ 10 cm (p < 0.05)、肿瘤大小> 10 cm (p < 0.01)、EGFR表达在61% ~ 80%范围内(p < 0.05)是HCC患者独立的生存预测因子。结论:EGFR过表达范围为61% - 80%是HCC患者的独立生存预测因子,这意味着这些患者可以从EGFR抑制中获益。然而,在本研究的任何病例中,外显子18-21中都没有EGFR突变,这表明单药EGFR靶向治疗HCC患者可能是不够的。
{"title":"Epidermal Growth Factor Receptor immunohistochemical expression in hepatocellular carcinoma without Epidermal Growth Factor Receptor exons 18–21 mutations","authors":"D. Nikolova, M. Trajkovska, Emilija Nikolovska Trpcevska, A. Eftimov, Rubens Jovanovik, V. Janevska","doi":"10.2478/rjim-2022-0006","DOIUrl":"https://doi.org/10.2478/rjim-2022-0006","url":null,"abstract":"Abstract Introduction: EGFR targeted therapies, have been proved beneficial for patients with HCC, nevertheless additional research on EGFR immunoexpresion and EGFR mutations is still needed, especially in population in which it has not been done yet. The aim of this study is to evaluate EGFR immunoexpression in HCC without EGFR exons 18–21 mutations and to evaluate its influence on survival in HCC patients in North Macedonia. Methods: We studied 31 cases of HCC for EGFR immunohistochemical expression and EGFR exons 18–21 mutations. The following clinical parameters were analyzed: Hepatitis B and C virus infection, presence of cirrhosis, tumor size, enlarged lymph nodes, metastases, alpha fetoprotein level and overall survival. Presence of the EGFR immunosignal (membranous and cytoplasmic) and the percentage of positive tumor cells in the entire tumor tissue specimen were semi-quantitatively determined. Results: Hepatitis B and C virus infection, tumor size, metastatic disease and EGFR immunoexpression have influence on patient’s survival. No EGFR exons 18–21 mutations were detected in this group of HCCs. EGFR expression of 61%–80% in tumor tissue significantly influenced survival of the patients (p < 0.01). Multiple Cox regression confirmed tumor size of 5–10 cm (p < 0.05), tumor size > 10 cm (p < 0.01) and EGFR expression in range of 61% to 80% (p < 0.05) as independent survival predictors in patients with HCC. Conclusion: EGFR overexpression in range of 61% to 80% was an independent survival predictor in patients with HCC, implying that these patients could benefit from EGFR inhibition. However, the absence of EGFR mutations in exons 18–21 in any of the cases of this study suggest that single drug EGFR targeted therapy in patients with HCC may be insufficient.","PeriodicalId":21463,"journal":{"name":"Romanian Journal of Internal Medicine","volume":"92 1","pages":"153 - 159"},"PeriodicalIF":1.9,"publicationDate":"2022-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90711825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Romanian Journal of Internal Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1